Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average): 2016-2025

Historic Shares Outstanding (Weighted Average) for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $265.1 million.

  • Akebia Therapeutics' Shares Outstanding (Weighted Average) rose 26.09% to $265.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.1 million, marking a year-over-year increase of 26.09%. This contributed to the annual value of $218.2 million for FY2024, which is 15.81% up from last year.
  • Akebia Therapeutics' Shares Outstanding (Weighted Average) amounted to $265.1 million in Q3 2025, which was up 0.96% from $262.6 million recorded in Q2 2025.
  • Akebia Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $265.1 million during Q3 2025, with a 5-year trough of $153.5 million in Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $214.6 million, with a median of $210.3 million in 2024.
  • Data for Akebia Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 26.09% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Shares Outstanding (Weighted Average) stood at $175.0 million in 2021, then increased by 5.14% to $184.0 million in 2022, then increased by 2.41% to $188.4 million in 2023, then grew by 15.81% to $218.2 million in 2024, then rose by 26.09% to $265.1 million in 2025.
  • Its last three reported values are $265.1 million in Q3 2025, $262.6 million for Q2 2025, and $236.2 million during Q1 2025.